Chronic lymphocytic leukemia (cll)

Show results for

Unknown (2290)
Genomics (711)
Transcriptomics (501)
Proteomics (64)
Methylation profiling (16)
Genomic (14)
Other (10)
Models (2)
Clinical (2)
Metabolomics (1)

Organisms

Homo sapiens (664)
Mus musculus (87)
Schizophyllum commune H4-8 (54)
Mycobacterium tuberculosis SP7 (54)
Oryza sativa Japonica Group (54)
Candidatus Endoriftia persephonae (54)
Mycobacterium tuberculosis SP10 (54)
Mycobacterium tuberculosis SP13 (54)
Mycobacterium tuberculosis SP22 (54)
Chlamydomonas reinhardtii (54)
Pyricularia oryzae P131 (54)
Enterococcus mundtii CRL35 (54)
Oncorhynchus tshawytscha (54)
Pseudomonas canadensis (54)
Strongylocentrotus purpuratus (54)
Influenza A virus (A/California/04/2009(H1N1)) (54)
Merkel cell polyomavirus (2)
Macacine alphaherpesvirus 1 (2)
JC polyomavirus (2)
Herpesvirus saimiri (strain 11) (2)
Betapolyomavirus macacae (2)
Human betaherpesvirus 6B (2)
human gammaherpesvirus 4 (2)
Betapolyomavirus hominis (2)
Human alphaherpesvirus 2 (2)
Human alphaherpesvirus 1 (2)
Human immunodeficiency virus 1 (2)
Human betaherpesvirus 5 (2)
Human gammaherpesvirus 8 (2)
Mus (1)

Organisms

Homo sapiens (362)
Mus musculus (54)

Repository

ENA (495)
geo (339)
biostudies-arrayexpress (272)
EGA (133)
pride (54)
dbGaP (14)
MassIVE (7)
EVA (2)
BioModels (1)
Cell Collective (1)
MetaboLights (1)

Tissue

B cell (32)
Blood (15)
Cell culture (9)
Peripheral blood mononuclear cell (7)
Blood cell (7)
B-cell chronic lymphocytic leukemia cell (2)
Stromal cell (2)
B-lymphocyte (2)
Primary cell (2)
Leukocyte (2)
Cell suspension culture (2)
B-lymphoma cell line (1)
Chronic lymphocytic leukemia cell (1)
Primary cell line cell (1)
Peripheral blood lymphocyte (1)
Monocyte (1)
Spleen (1)
Blood plasma (1)

Disease

Chronic lymphocytic leukemia (44)
Lymphoma (6)
Normal (3)
B-cell chronic lymphocytic leukemia (2)
Chronic lymphoid leukemia (1)
CLL (1)
Mantle cell lymphoma (1)
Chronic lymphocytic leukemia (CLL) (1)
Anaplastic large cell lymphoma has DiseaseStaging II (1)
CHRONIC LYMPHOCYTIC LEUKEMIA (1)
CLL cells from female patients (1)
Colon cancer (1)
Mycoses (1)
Carcinoma (1)
Follicular lymphoma (1)
Richter's syndrome (1)
Mantle cell lymphoma (1)
Burkitt lymphoma (1)
Acute myeloid leukemia (1)
Acute leukemia (1)

Technology Type

Mass Spectrometry (54)
Shotgun proteomics (35)
Bottom-up proteomics (6)
SWATH MS (6)
Gel-based experiment (4)
Affinity purification coupled with mass spectrometry proteomics (4)
Illumina HiSeq 2500 (3)
Data-dependent acquisition (3)
Illumina HiSeq 2500, ILLUMINA (2)
ILLUMINA, Illumina HiSeq 2000 (2)
Immunopeptidomics (2)
Illumina CytoSNP, Illumina HumanOmni2.5, ILLUMINA, Illumina 450k, Illumina HiSeq 2000 (1)
Illumina MiSeq, ILLUMINA (1)
Illumina HiSeq 3000 (1)
Illumina Genome Analyzer IIx, Illumina Genome Analyzer II, Affymetrix U219 (1)
Affymetrix U219, Illumina HumanMethylation450, Illumina Genome Analyzer IIx (1)
Illumina Genome Analyzer II, Affymetrix snp 6.0, Illumina Genome Analyzer IIx, GPL570, Affymetrix GeneChip Human Genome U133 plus 2.0 (1)
Illumina HiSeq 2000, Illumina Genome Analyzer II (1)
Illumina HiSeq 2000 (1)
Mass spectrometry (1)
Proteogenomics (1)
HDMSE (1)
Top-down proteomics (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)
Data-independent acquisition (1)

Instrument Platform

Illumina NovaSeq 6000 (12)
Illumina HiSeq 2000 (8)
Illumina HiSeq 2500 (6)
Q Exactive (6)
NextSeq 500 (5)
Illumina HiSeq 4000 (4)
Axon GenePix 4000B scanner (2)
Scanning hardware (2)
Illumina MiSeq (2)
Affymetrix GCS 3000 (1)
GeneChip® Pico Kit (Affymetrix) (1)
Affymetrix Clariom™ S (400 Format) (1)
Microarray scanner system (1)
Covaris S2 (1)
454 GS FLX (1)
GCS3000 (1)
Affymetrix HG-U133 Plus 2.0, fluidics sstation 450 (1)
ScanArray 4000XL [PerkinElmer] (1)
Ion S5 (1)
Ion Torrent PGM (1)
MALDI SYNAPT G2-Si (1)
Orbitrap Fusion Lumos (1)
Q Exactive Plus (1)

Publication Date

2013 (58)
2015 (54)
2011 (44)
2022 (41)
2014 (41)
2026 (40)
2021 (38)
2009 (37)
2024 (36)
2016 (33)
2012 (33)
2023 (29)
2025 (27)
2019 (27)
2020 (26)
2008 (24)
2017 (22)
2018 (20)
2010 (20)
2007 (13)
2005 (7)
2006 (4)
2004 (1)

CHEBI ID

CHEBI:18222 (1)
CHEBI:133583 (1)
CHEBI:9908 (1)
CHEBI:81240 (1)
CHEBI:45969 (1)
CHEBI:15245 (1)
CHEBI:139138 (1)
CHEBI:166739 (1)
CHEBI:9159 (1)
CHEBI:33527 (1)
CHEBI:604731 (1)
CHEBI:89836 (1)
CHEBI:133733 (1)
CHEBI:8227 (1)
CHEBI:36011 (1)
CHEBI:141030 (1)
CHEBI:133677 (1)
CHEBI:46215 (1)
CHEBI:133693 (1)
CHEBI:37659 (1)
CHEBI:132479 (1)
CHEBI:165558 (1)
CHEBI:132476 (1)
CHEBI:90344 (1)
CHEBI:134543 (1)
CHEBI:165892 (1)
CHEBI:84415 (1)
CHEBI:165872 (1)
CHEBI:28132 (1)
CHEBI:88824 (1)

Metabolite Name

Xylose (1)
Xanthurenate (1)
Vanillic alcohol sulfate (1)
Vanillate (1)
Ursolic acid (1)
Ursodeoxycholate (1)
Ursocholate (1)
Tyrosol (1)
Tyramine O-sulfate (1)
Tryptophan betaine (1)
Tricarballylate (1)
Thymidine 5'-monophosphate (1)
Tauroursodeoxycholate (1)
Taurolithocholate 3-sulfate (1)
Taurolithocholate (1)
Taurohyodeoxycholic acid (1)
Taurodeoxycholate (1)
Taurocholenate sulfate* (1)
Taurocholate (1)
Taurochenodeoxycholate (1)
Syringic acid (1)
Stigmasterol (1)
Stearoyl ethanolamide (1)
Stearidonate (18:4n3) (1)
Sphingosine (1)
Soyasaponin III (1)
Soyasaponin II (1)
Soyasaponin I (1)
Solanidine (1)
Sinensetin (1)

First Public Date

2014 (109)
2024 (45)
2026 (43)
2022 (40)
2021 (36)
2020 (34)
2025 (31)
2023 (29)
2015 (29)
2019 (27)
2018 (24)
2016 (22)
2017 (17)
2013 (9)

Modelling Approach

Ordinary differential equation model (1)

Study status

Terminated (1)
Active, not recruiting (1)

Lab affiliation

University of Vienna, Faculty of Chemistry, Department of Analytical Chemistry (8)
Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany (3)
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany (2)
Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland (2)
Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC, UMR 7178, Strasbourg, France (2)
Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany (2)
University of Nebraska Medical Center (2)
Wellcome Trust/ MRC Cambridge Stem Cell Institute & Department of Haematology, Univeristy of Cambridge, Cambridge, UK. (1)
Queen's University Belfast, UK (1)
University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Center for Molecular Medicine Cologne; Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, 50931 Cologne, Germany (1)
CDSS Bioanalytical Facility, Liverpool Shared Research Facilities, University of Liverpool (1)
Head of the Department, Proteomics Core (1)
Laboratory of Systems Biology and Genetics, Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland (1)
Head of Proteomics CRUK Cambridge Institute Cambridge University Robinson Way Cambridge CB2 0RE UK Email: clive.d’santos@cruk.cam.ac.uk Phone: +44 1223 769677 (1)
Finley and Gygi lab - Cell Biology Department - Harvard Medical School (1)
Laboratory 11 and Proteomics Unit. Cancer Research Center. Salamanca. Spain (1)
Max Planck Institute for Metabolism Research Cologne, 50931 Cologne, Germany (1)
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden (1)
Department of Microbiology and Immunology, The Scripps Research Institute; Jupiter, FL, USA (1)
MRC Centre for Drug Safety Science, Dept Molecular & Clinical Pharmacology, University of Liverpool (1)
MRC Centre for Drug Safety Science, Dept Molecular and Clincal Pharmacology, University of Liverpool (1)
MRC Centre for Drug Safety Science, Dept Molecular & Clinical Pharmacology (1)
Department of Chemical & Systems Biology, Stanford University, USA (1)
Professor of Immunology (1)
Academia Sinica, Institute of Biological Chemistry (1)
Institut Pasteur de Montevideo (1)
Professor, Associate Director of Academic Affairs, Division of Hematology, Professor of Medicine, Dept of Internal Medicine (1)
Institute of Biological Chemistry, Academia Sinica (1)
Department of Oncology-Pathology, Karolinska Institutet and Science for Life Laboratory (1)
Division of Hematology, Department of Medicine, Stanford University School of Medicine Department of Chemistry, Northwestern University (1)

Keyword

Rituximab (1)
Lenalidomide (1)

IsPrivate

False (1)

Submitter Keywords

Immuno-oncology (1)

Modification

Not available (1)

Study type

Transcription profiling by array (162)
RNA-seq of coding RNA (24)
Comparative genomic hybridization by array (21)
MicroRNA profiling by array (8)
DNA-seq (8)
ChIP-seq (7)
Methylation profiling by array (7)
Genotyping by array (6)
Methylation profiling by high throughput sequencing (3)
RNA-seq of total RNA (3)
Unknown experiment type (2)
Animal - One-color microarray (2)
ChIP-chip by tiling array (2)
Transcription profiling by RT-PCR (2)
Other (2)
Proteomic profiling by array (2)
RNA-seq of coding RNA from single cells (2)
Interventional (2)
RNA-seq of non coding RNA from single cells (1)
Human - Two-color microarray (1)
Human - High-throughput sequencing (1)
Animal - High-throughput sequencing (1)
ChIP-chip by array (1)
MicroRNA profiling by high throughput sequencing (1)
ATAC-seq (1)
RIP-seq (1)
RNA-seq of non coding RNA (1)

Release Date

2022 (251)
2021 (240)
2023 (221)
2025 (176)
2019 (171)
2024 (170)
2020 (167)
2016 (155)
2015 (154)
2018 (139)
2017 (132)
2014 (126)
2013 (107)
2012 (72)
2011 (68)
2010 (61)
2009 (46)
2008 (32)
2026 (25)
2007 (18)
2005 (13)
2006 (9)
2004 (3)
2002 (2)
1997 (2)
2001 (1)
1998 (1)

Location

United States (2)

Previous page
1 / 362
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 362
Next page

Sort by:

Relevance

Page size

Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is still incurable despite the development of novel therapeutic strategies. This reflects the incomplete understanding of the pathophysiology of this disease. In order to get more detailed insights into CLL development, ...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

MSV000082941 | MassIVE

Transcription profiling of human chronic lymphocytic leukemia cells treated with valproic acid

Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have recently been proposed as potential new therapies for hematological malignancies. Chronic Lymphocytic Leukemia (CLL) remains incurable despite the introduction of new treatments. CLL cells are characterized by an apoptosis ...

ORGANISM(S): Homo sapiens

2009-09-17 | E-GEOD-14973 | biostudies-arrayexpress

Transcription profiling of human chronic lymphocytic leukemia patients expressing high or low levels of ZAP70 mRNA

Comparison of Chronic Lymphocytic Leukemia patients expressing high or low levels of ZAP70 mRNA: prognostic factors and interaction with the microenvironment. Zeta-associated protein 70 (ZAP70) is a widely recognized prognostic factor in chronic lymphocytic leukemia (CLL), but mechanisms by which it...

ORGANISM(S): Homo sapiens

2009-04-25 | E-GEOD-12734 | biostudies-arrayexpress

Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia – unexpected expression pattern of the RHO GTPase activator ARHGAP20

In chronic lymphocytic leukemia (CLL), 13q14 and 11q22-23 deletions are found in 2/3 of the cases. 11q22-23 deletions are associated with poor survival, whereas 13q14 deletions as single abnormality are often found in indolent disease forms. The molecular basis for this difference in prognosis is no...

ORGANISM(S): Homo sapiens

2011-10-13 | E-GEOD-25571 | biostudies-arrayexpress

Comparative genomic hybridization of human chronic lymphocytic leukemia CLL patients and subtypes of del13q14

Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous illness with a variable clinical course. Loss of chromosomal material on chromosome 13 at cytoband 13q14 is the most frequent genetic abnormality in CLL, but the molecular aberrations underlying del13q14 in CLL remain incompletely...

ORGANISM(S): Homo sapiens

2008-06-16 | E-GEOD-9250 | biostudies-arrayexpress

Transcription profiling of human CLL - a genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia - super series

This SuperSeries is composed of the following subset Series:; GSE10137: A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia (Mayo_Ohio); GSE10138: A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leuk...

ORGANISM(S): Homo sapiens

2009-11-09 | E-GEOD-10139 | biostudies-arrayexpress

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia

Genomic aberrations are of predominant importance to the biology and clinical outcome of patients with chronic lymphocytic leukemia (CLL), and FISH-based genomic risk classifications are routinely used in clinical decision making in CLL. One of the known limitations of CLL FISH is the inability to ...

ORGANISM(S): Homo sapiens

2011-11-29 | E-GEOD-30777 | biostudies-arrayexpress

Detection of chromothripsis-like patterns from custom array platform for chronic lymphocytic leukemia diagnosis (qchip Hemo custom array v3)

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries. The main genetic alterations associated to this disease are loss of 13q14, loss of 11q23, trisomy 12 and, less frequently, 17p13 losses, and are routinely studied using fluorescence in situ hybridization. These ge...

ORGANISM(S): Homo sapiens

2015-08-31 | E-GEOD-66922 | biostudies-arrayexpress

Transcription profiling of human chronic lymphocytic leukemia samples from patients with stable or progressive disease

Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy, characterized by a variable clinical course. While clinical and laboratory parameters are increasingly being used to refine prognosis, they do not accurately predict response to commonly used therapy. We used gene expression profilin...

ORGANISM(S): Homo sapiens

2009-11-11 | E-GEOD-10138 | biostudies-arrayexpress

Transcription profiling of human chronic lymphocytic leukemia samples to improve prognosis and predict therapeutic response

ORGANISM(S): Homo sapiens

2009-11-11 | E-GEOD-10137 | biostudies-arrayexpress

Previous page
1 / 362
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 362
Next page

Sort by:

Relevance

Page size

3611 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Keyword

IsPrivate

Submitter Keywords

Modification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets